Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
KANT similar filings
- 8 Apr 21 Entry into a Material Definitive Agreement
- 31 Mar 21 Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Developments
- 10 Feb 21 Yumanity Therapeutics Provides Update on Its Lead Parkinson’s Disease Clinical Program, YTX-7739
- 3 Feb 21 Other Events
- 11 Jan 21 Regulation FD Disclosure
- 30 Dec 20 Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
- 16 Dec 20 Other Events
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-228529 and 333-224180) and Form S-8 (Nos. 333-237181, 333-230155, 333-223664, 333-218544 and 333-210521) of Yumanity Therapeutics, Inc. (formerly known as Proteostasis Therapeutics, Inc.) of our report dated September 23, 2020 relating to the financial statements of Yumanity Holdings, LLC, which appears in this Current Report on Form 8-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 3, 2021